Chemical NamePretomanid
Dosage FormTablet (oral; 200 mg)
Drug ClassAntibacterials
CompanyTB Alliance
Approval Year2019


  • Pretomanid is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).
Last updated on 10/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Pretomanid Prescribing Information 2019TB Alliance
Document TitleYearSource
Treatment of highly drug-resistant pulmonary tuberculosis. 2020New England Journal of Medicine